Department of Critical Care Medicine, Shaoxing Second Hospital, Zhejiang University , FanYaoq998@hotmail.com
Abstract: (57 Views)
Background:Severe traumatic brain injured (STBI) is a leading reason for death and long-term disabilities, and improved real-time management of intracranial pressure (ICP) is necessary. This study evaluated the efficacy of drug therapy with ultrasound-guided in patients with STBI by measuring optic nerves sheath diameters (ONSD). Materials and Methods: This retrospective case-control study involved 263 patients with STBI who were treated between March 2019 and June 2021. Patients were categorized in an ultrasound group (n=125), which received ONSD-guided therapy, and a regular group (n=138), which received conventional treatment. Neurogenic and inflammatory markers, clinical scales, and functional recovery metrics were assessed. Results: The ultrasound group showed remarkably improved early-treatment outcomes, such as decreased abnormal breathing (27.20% vs. 40.58%, P=0.022) and lower ICP (54.40% < 350 mmHg vs. 40.58%, P=0.025). This group also showed increased neurogenic factors (brain-derived neurotrophic factors (BDNF) and nerve growth factors (NGF)) and notable decreases in inflammatory indicators like tumor necrosis factor α (TNF-α) (P<0.05). Post-treatment neurological scores were better in the ultrasound group (National Institutes of Health Stroke Scale (NIHSS): 18.32 vs. 18.96 (P=0.018); Glasgow Coma Scale (GCS): 11.19 vs. 10.54 (P=0.007)). Functional assessments (Fugl-Meyer Assessment (FMA), Berg Balance Scale (BBS), Modified Barthel Indexs (MBI)) and quality of life (Simplified Form of Health Questionnaire-36 (SF-36)) indices also favored the ultrasound group. Conclusion: Ultrasound-guided ONSD measurement enhances real-time ICP management in drug therapy for patients with STBI. The measurement has positive effects on neurogenic and inflammatory profiles, functional recoveries, and quality of life.
Fan Y, Niu J, Lu Q. Ultrasound measurement of sheath nerve diameter for guided drug therapy for severe craniocerebral injury. Int J Radiat Res 2025; 23 (4) :1119-1123 URL: http://ijrr.com/article-1-6823-en.html